<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31178823</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Excellent Response to Plasma Exchange in Three Patients With Enterovirus-71 Neurological Disease.</ArticleTitle><Pagination><StartPage>548</StartPage><MedlinePgn>548</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">548</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2019.00548</ELocationID><Abstract><AbstractText>The clinical spectrum of Enterovirus-71-associated neurological disease includes acute flaccid paralysis, encephalomyelitis, or brainstem encephalitis with autonomic dysfunction. As no specific antiviral treatments are available, intravenous human immunoglobulin is used in early stages of the illness, decreasing serum proinflammatory cytokines, and improving clinical outcomes. Plasma exchange aims to eliminate pathogenic autoantibodies and proinflammatory cytokines, and is used in diverse immune-mediated neurologic conditions. However, its effect in Enterovirus-71 infections is unknown. We report three cases of severe Enterovirus-71 neurological disease treated with plasma exchange during an outbreak in Catalonia (Spain) in 2016. We observed a striking improvement in all three patients within 48 h of starting plasma exchange. Patients received four to six sessions every other day. Good outcomes were confirmed at the 1-year follow-up visit. Our observations suggest that plasma exchange is an effective complementary therapy for severe Enterovirus-71 neurological disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pascual-Go&#xf1;i</LastName><ForeName>Elba</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josa</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launes</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Infectious Diseases Research Group, CIBER of Epidemiology and Public Health (CB15/00067 Group), Institut de Recerca Pedi&#xe0;trica Sant Joan de D&#xe9;u, Esplugues, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querol</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Cuerpo</LastName><ForeName>Marga</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>M Alba</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Banc de Sang i Teixits, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Iolanda</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatric Infectious Diseases Research Group, CIBER of Epidemiology and Public Health (CB15/00067 Group), Institut de Recerca Pedi&#xe0;trica Sant Joan de D&#xe9;u, Esplugues, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Hospital Sant Joan de D&#xe9;u, Esplugues de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tur&#xf3;n-Vi&#xf1;as</LastName><ForeName>Eul&#xe0;lia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">brainstem encephalitis with cardiorespiratory failure</Keyword><Keyword MajorTopicYN="N">encephalomyelitis</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">plasma exchange</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31178823</ArticleId><ArticleId IdType="pmc">PMC6542981</ArticleId><ArticleId IdType="doi">10.3389/fneur.2019.00548</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. (2010) 9:1097&#x2013;105. 10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa JF, Yeng C.
A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease.
Geneva, Switzerland: World Health OrganizationWestern Pacific Region;  (2011). ISBN 978 92 9061 525 5. Available online at: http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf (accessed October 1, 2018)</Citation></Reference><Reference><Citation>Teoh HL, Mohammad SS, Britton PN, Kandula T, Lorentzos MS, Booy R, et al. . clinical characteristics and functional motor outcomes of enterovirus 71 neurological disease in children. JAMA Neurol. (2016) 73:300&#x2013;7. 10.1001/jamaneurol.2015.4388</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4388</ArticleId><ArticleId IdType="pubmed">26785318</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. (1974) 129:304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas-Alba D, de Sevilla MF, Valero-Rello A, Fortuny C, Garcia-Garcia JJ, Ortez C, et al. . Outbreak of brainstem encephalitis associated with enterovirus-A71 in Catalonia, Spain (2016): a clinical observational study in a children's reference centre in Catalonia. Clin Microbiol Infect. (2017) 23:874&#x2013;81. 10.1016/j.cmi.2017.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2017.03.016</ArticleId><ArticleId IdType="pubmed">28344164</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control 
Enterovirus Detections Associated With Severe Neurological Symptoms in Children and Adults in European Countries. [Internet] 2016. Available online at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/01-08-2016-RRA-Enterovirus%2071-Spain%2C%20France%2C%20Netherlands.pdf(Accessed October, 17 2018)</Citation></Reference><Reference><Citation>Wang SM, Lei HY, Liu CC. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin Dev Immunol. (2012) 2012:876241. 10.1155/2012/876241</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/876241</ArticleId><ArticleId IdType="pmc">PMC3432373</ArticleId><ArticleId IdType="pubmed">22956971</ArticleId></ArticleIdList></Reference><Reference><Citation>Subdirecci&#xf3; General de Vigil&#xe0;ncia i Resposta a Emerg&#xe8;ncies de Salut P&#xfa;blica de Catalunya 
Protocol D'actuaci&#xf3; Davant Casos D'enterovirus en Poblaci&#xf3; Pedi&#xe0;trica. [Internet] 2016. Available from: http://salutweb.gencat.cat/web/.content/home/canalsalut/enterovirus/protoenterovirus.pdf. (Accessed October, 17 2018)</Citation></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, et al. . Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. (2003) 188:564&#x2013;70. 10.1086/376998</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao P, Wu X, Li H, Wu Z, Yang Z, Yao H. Clinical significance of inflammatory cytokine and chemokine expression in hand, foot and mouth disease. Mol Med Rep. (2017) 15:2859&#x2013;66. 10.3892/mmr.2017.6324</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.6324</ArticleId><ArticleId IdType="pubmed">28447721</ArticleId></ArticleIdList></Reference><Reference><Citation>Defresne P, Meyer L, Tardieu M, Scalais E, Nuttin C, De Bont B, et al. . Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry. (2001) 71:272&#x2013;4. 10.1136/jnnp.71.2.272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.71.2.272</ArticleId><ArticleId IdType="pmc">PMC1737519</ArticleId><ArticleId IdType="pubmed">11459911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang MC, Wu JM, Chen CT, Wang JN, et al. . Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol. (2005) 39:219&#x2013;23. 10.1002/ppul.20157</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.20157</ArticleId><ArticleId IdType="pubmed">15635619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang MC, Su LY, Lin HC, Yu CK, et al. . Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol. (2006) 37:47&#x2013;52. 10.1016/j.jcv.2006.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2006.05.009</ArticleId><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SL, Rabinstein AA. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients. Neurol Res. (2015) 37:593&#x2013;8. 10.1179/1743132815Y.0000000017</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132815Y.0000000017</ArticleId><ArticleId IdType="pubmed">25751423</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Keller JR, Nunneley CE, Muscal E, Braun MC, Srivaths P, et al. . Therapeutic Plasma Exchange Use in Pediatric Neurologic Disorders at a Tertiary Care Center: A 10-Year Review. J Child Neurol. (2018) 33:140&#x2013;5. 10.1177/0883073817749368</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073817749368</ArticleId><ArticleId IdType="pubmed">29334853</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. . Guidelines on the Use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue. J Clin Apher. (2016) 31:149&#x2013;62. 10.1002/jca.21470</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21470</ArticleId><ArticleId IdType="pubmed">27322218</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. (1992) 326:1123&#x2013;9. 10.1056/NEJM199204233261705</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199204233261705</ArticleId><ArticleId IdType="pubmed">1552913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>